The Future of Biotics: Individualized Probiotic, Prebiotic, and Postbiotic Solutions

Introduction: The gut microbiome plays a critical role in health and disease, influencing metabolic, gastrointestinal, and immune functions. With growing evidence supporting the role of microbiome-targeted therapies, personalized biotics, probiotics, prebiotics, and postbiotics tailored to individual microbial profiles are emerging as a novel approach in precision medicine. Methods: A narrative review was conducted using studies published between January 2019 and January 2024 from databases including PubMed, Scopus, Web of Science, and Google Scholar. Inclusion criteria focused on clinical trials, systematic reviews, or metaanalyses involving personalized biotic interventions in humans. Data extraction included intervention types, populations, outcomes, and study design. Results: Thirty-four studies met the inclusion criteria. Personalized probiotics showed up to a 30% reduction in inflammatory symptoms in IBD patients and improvements in metabolic and mental health markers. Selective prebiotics demonstrated a 25% decrease in obesity-related biomarkers and supported microbial diversity. Postbiotics exhibited stable immunomodulatory effects with better safety and storage profiles. However, challenges include high costs, methodological heterogeneity, and lack of standardization. Discussion: Personalized biotics show promising therapeutic potential across diverse health conditions, particularly were microbiome variability impacts treatment response. Emerging technologies such as metagenomics and biomarker profiling support the feasibility of individualized approaches. Conclusion: Personalized biotics represent a transformative step in gut health and precision medicine. Ongoing clinical validation and standardization are essential to translating this approach into routine healthcare.